Remitro IV infusion 300μg, from Eisai, contains Denileukin diftitox (genetical recombination). This fusion protein targets IL-2 receptors on cancer cells, inhibiting protein synthesis and inducing cell death. It is an injectable drug supplied as 300μg per bottle, with YJ code 4291456D1027.
Remitro IV infusion 300μg
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →